Page 15 - emap_newsletter_V2

eMAP – electronic EHA Medical HemAtology Program

S255 EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH
RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II
BIANCA STUDY

S260 A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN
RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE
FRENCH DESCAR-T REGISTRY

P1111 COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN
RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

P1124 MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED
OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

P1169 ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY
AND OUTPERFORMS MORE COMPLEX SCORES

P1174 THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS
PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH
ANTI-CD19 CAR-T CELLS

P1197 AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF
RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14
STUDY

P1198 ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING
SECOND-LINE AXICABTAGENE CILOLEUCEL VS. STANDARD OF CARE IN PATIENTS WITH RELAPSED/
REFRACTORY LARGE B-CELL LYMPHOMA

P1204 TREATMENT PATTERNS AND REAL-WORLD OUTCOMES IN PATIENTS (PT) WITH LARGE B-CELL
LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE (2L) THERAPY

P1447 INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL
LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR
PRODUCT CHOICE

P1452 THE PRELIMINARY SAFETY AND EFFICACY STUDY OF SC-U02, A NON-VIRAL GENOME TARGETING,
ANTI-CD19 UNIVERSAL CAR-T PRODUCT, IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL
LYMPHOMA PATIENTS

P1458 PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-
DIRECTED CAR T-CELL THERAPY FOR R/R LBCL

P1461 CAR-T VS. STANDARD OF CARE AS SECOND LINE TREATMENT FOR LARGE B CELL LYMPHOMA: A
SYSTEMATIC REVIEW AND META-ANALYSIS

P1462 POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS
WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD
EXPERIENCE

P1710 LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL
LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM
THE PHASE 2 PILOT STUDY

P1717 HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK
PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2
CLINICAL TRIAL (LOTIS 2)

P1744 ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL
THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)

LB2364 PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED
OR REFRACTORY LARGE B-CELL LYMPHOMA: A PHASE 2 STUDY

Cellular and immunotherapies (CAR T cells, CELMoDs, bispecifics) for RRMM

S173 T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A
NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA

TABLE OF CONTENTS 15